Orgovyx was approved … Starting the drug can cause a transient decrease in heart rate and delays in atrioventricular conduction, so clinicians are advised to titrate up the dose to reach the maintenance dosage. The R&D crown for greatest success at the FDA in 2019 is going to have to be shared. The first was Nexletol (bempedoic acid, Esperion), which is the first oral, once-daily, non-statin LDL-cholesterol lowering medicine approved in nearly 20 years. When it comes to innovation in the development of new drugs and therapeutic biological products, FDA’s Center for Drug Evaluation and Research (CDER) supports the pharmaceutical industry at every step of the process. It takes over $2.6 billion for a manufacturer to get a new drug from the laboratory onto the pharmacy shelf, according to the Tufts Center for the Study of Drug Development. These new drug approvals are listed below, starting with the most recent: 1. 04/17/2020 TUKYSA NDA #213411 TUCATINIB Type 1 - New Molecular Entity Priority SEAGEN 04/17/2020 PEMAZYRE NDA #213736 PEMIGATINIB Type 1 - New Molecular Entity Priority INCYTE CORP 04/22/2020 04/24 The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Many of these products contain active moieties that have not been approved by FDA previously, either as a single ingredient drug or as part of a combination product; these products frequently provide important new therapies for patients. Previously approved medications that have gained new FDA approval for the treatment of additional medical conditions. Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. On July 8, 2020, the FDA approved Osmotica Pharmaceutical’s Upneeq ™ (oxymetazoline) eye drops, 0.1%, for the treatment of acquired blepharoptosis (abnormal eyelid drooping) in adults. Setting New drugs approved by the FDA and EMA between 2007 and 2017, with follow-up through 1 April 2020… In late February, the FDA approved two unique non-statin cholesterol-lowering medications from the same company. Here’s a roundup of the novel drugs that all doctors should know about: .css-1vg6q84{font-weight:700;}.css-5rtkqm{box-sizing:border-box;margin:0;min-width:0;color:#202529;line-height:1.75;-webkit-letter-spacing:0;-moz-letter-spacing:0;-ms-letter-spacing:0;letter-spacing:0;font-family:Open Sans;font-size:16px;overflow-wrap:break-word;word-wrap:break-word;-webkit-hyphens:auto;-moz-hyphens:auto;-ms-hyphens:auto;hyphens:auto;padding:0;margin:0;margin-bottom:16px;font-weight:700;}Nexletol and Nexlizet for high cholesterol. In mid-April, the FDA OK’d Pemazyre (pemigatinib, Incyte Corporation), the first approved treatment for adults with certain types of previously treated advanced cholangiocarcinoma—a rare form of cancer that forms in bile ducts. However, recently the FDA approved a new insomnia medication that may serve as an alternative. More Drugs Approved in May by the FDA According to RTT News, about 13 new drugs were approved by the FDA in May this year, which is significantly higher than the eight novel drugs approved … © 2021 M3 USA Corporation. Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA … So far, the agency has approved 16 new drugs in 2020. For both drugs, adverse events were mild to moderate in severity and comparable to those reported in patients on placebo. In a study that included patients with episodic and chronic migraine, the researchers found that patients taking 1 dose of Nurtec ODT (75 mg) every other day had 4.5 fewer monthly migraine days while those taking a placebo had 3.7 fewer monthly migraine days. Zeposia also reduced the size and number of brain lesions more than interferon beta-1a. Drugs@FDA: FDA-Approved Drugs Share Tweet Linkedin Pin it More sharing options Linkedin Pin it Email Print Home | Previous Page New Drug Application (NDA): 213702 Company: Email Products on … See Drugs@FDA for information about all of CDER’s approved drugs and biological products. This compares with 11 drugs approved by the regulator last year. The FDA approved a whopping 48 novel drugs in 2020. Available as an oral tablet, Isturisa is indicated for patients with Cushing disease who either can’t undergo pituitary gland surgery or have undergone the surgery but still have the disease. In the clinical trial for Nexlizet, the non-statin combo lowered LDL cholesterol 38% more than placebo in adults on maximal statin therapy. Sixty-four percent of patients had grade 3 or worse adverse events, including hypophosphatemia, arthralgia, stomatitis, hyponatremia, abdominal pain, and fatigue. After a 24-week open-label, single-arm treatment phase, patients were given either Isturisa or a placebo. Oxlumo (lumasiran) is a HAO1-directed small interfering ribonucleic acid (siRNA) indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients. Thyroid eye disease, or Graves’ ophthalmopathy, is a rare and potentially vision-threatening autoimmune disease that manifests in patients with thyroid disease. Of those who received the study drug, 71% to 83% of patients in both studies had > 2-mm reduction in proptosis compared with 10% to 20% who received placebo. To see the FDA-approved conditions of use [e.g., indication(s), population(s), dosing regimen(s)] for each of these products, see the most recent FDA-approved Prescribing Information (click on the Drug Name) . The following database contains a listing of drugs approved by the Food and Drug Administration (FDA) for sale in the United States. To treat HIVPress ReleaseDrug Trials Snapshot. In late November—at least 3 months earlier than expected— the FDA approved a drug to treat sickle cell disease. Given SC immediately before or within 20 minutes of beginning meals, it is indicated to For this reason, CDER supports innovation and plays a key role in helping to advance new drug development. The .gov means it’s official.Federal government websites often end in .gov or .mil. Inmazeb The FDA approved … An official website of the United States government, : The second was Nexlizet (bempedoic acid and ezetimibe, Esperion), the first combination non-statin LDL-cholesterol lowering medicine ever approved. New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products, Recalls, Market Withdrawals and Safety Alerts, New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products, Center for Biologics Evaluation and Research, To treat actinic Keratosis of the face or scalp, To treat patients with hereditary angioedema, For detection and localization of prostate cancer, To treat high-risk refractory or relapsed neuroblastoma, To treat obesity and the control of hunger associated with pro-opiomelanocortin deficiency, a rare disorder that causes severe obesity that begins at an early age, atoltivimab, maftivimab, and odesivimab-ebgn, To help detect certain types of neuroendocrine tumors, To treat neuromyelitis optica spectrum disorder, To treat Chagas disease in certain pediatric patients younger than age 18, To treat relapsed or refractory diffuse large B-cell lymphoma, To treat adult patients with myelodysplastic syndromes, To treat molecularly long-chain fatty acid oxidation disorders, To treat metastatic small cell lung cancer, Diagnostic agent for patients with Alzheimer’s disease, Diagnostic imaging agent for certain patients with breast cancer, To treat advanced gastrointestinal-stromal tumors, To treat patients with non small cell lung cancer, To treat patients with Parkinson’s disease experiencing “off” episodes, To treat adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease, To treat certain patients with cholangiocarcinoma, a rare form of cancer that forms in bile ducts, To treat advanced unresectable or metastatic HER2-positive breast cancer, To treat neurofibromatosis type 1, a genetic disorder of the nervous system causing tumors to grow on nerves, To treat relapsing forms of multiple sclerosis, To treat adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease, To help prevent nausea and vomiting after surgery, For the preventive treatment of migraine in adults, To treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C, To treat chronic idiopathic constipation (CIC) in adults, To treat adults with unresectable or metastatic gastrointestinal stromal tumor (GIST), Some of these products are innovative new products that never have been used in clinical practice. The FDA is approving more and more drugs every year—and 2020 appears to be no exception. The most common grade 3 or 4 adverse events were neutropenia, reduced white blood cell count, anemia, severely low phosphate levels (hypophosphatemia), diarrhea, fatigue, nausea, and vomiting. Certain drugs are classified as new molecular entities (“NMEs”) for purposes of FDA … The company plans to seek FDA approval to include this indication to the drug’s usage. Below is a listing of new molecular entities and new therapeutic biological products approved by CDER in 2020. During the clinical trial, patients received a daily pemigatinib tablet for 14 consecutive days, followed by 7 days off, in 21-day cycles. Tepezza is administered as a 20 mg/kg intravenous infusion once every 3 weeks for a total of 8 infusions. Imfinzi (durvalumab) Injection New Dosage Regimen: November 18, 2020 Date of Original Approval: May 1, 2017 The drug is a calcitonin gene-related peptide (CGRP) receptor antagonist; CGRP is believed to be a root cause of migraine. Xcopri will be available for adults 18 years and older. Partial-onset seizures are one of the most common types of seizures. Trodelvy for metastatic triple-negative breast cancer In its first few FDA tests, Trodelvy (sacitizumab govitecan-hziy) earned orphan drug, fast track, and breakthrough therapy designations.. For example, CDER classifies biological products submitted in an application under section 351(a) of the Public Health Service Act as NMEs for purposes of FDA review, regardless of whether the Agency previously has approved a related active moiety in a different product. The drug, named lemborexant (Dayvigo), was found to particularly help seniors stay asleep. The drug showed its efficacy in a phase 2, single-arm multicenter trial that enrolled 108 patients with metastatic triple-negative breast cancer who had received a median of 3 previous treatments for metastatic disease. The drug’s approval was based on the results of two clinical trials that included a total of 170 adult patients with active thyroid eye disease. At the end of this randomized withdrawal phase, 86% of patients given Isturisa maintained cortisol levels within normal limits compared with 30% of patients given a placebo. The FDA approved 53 new drugs this year, including 20 with indications related to oncology. Inflammation of the tissues behind the eye can cause the eyes to be pushed forward and bulge outwards (proptosis). A number of novel drugs are expected to gain FDA approval in 2020—and one of them has already been approved, weeks before the New Year. Median progression-free survival was 5.5 months (95% CI: 4.1-6.3) and overall survival was 13.0 months (95% CI: 11.2-13.7). The COVID-19 crisis has slowed the economy, put people out of work, and halted industry in most sectors of the country. Nurtec ODT (rimegepant, Biohaven) was approved by the FDA only 2 months ago—but there’s already a new development. The FDA approved Eli Lilly’s Reyvow (lasmiditan) for acute treatment of migraine with or without aura, and it is expected to be available in January 2020. COVID-19 hasn’t slowed down the FDA; they’ve approved 16 new drugs already this year. “Our staff is teleworking full time and continuing to meet virtually with drug developers, academic investigators, and patient advocates to push forward the coordinated review of drugs, biologics, and devices,” an FDA spokesperson recently told .css-1msjh1x{font-style:italic;}.css-rwxczz{box-sizing:border-box;margin:0;min-width:0;color:#202529;line-height:1.75;-webkit-letter-spacing:0;-moz-letter-spacing:0;-ms-letter-spacing:0;letter-spacing:0;font-family:Open Sans;font-size:16px;overflow-wrap:break-word;word-wrap:break-word;-webkit-hyphens:auto;-moz-hyphens:auto;-ms-hyphens:auto;hyphens:auto;padding:0;margin:0;margin-bottom:16px;font-style:italic;}Targeted Oncology. Design Retrospective cohort study. In adults on maximal lipid-lowering therapy, researchers reported that Nexletol lowered LDL cholesterol 17% more than placebo. It is a selective catechol-O-methyltransferase (COMT) inhibitor for use as The drug’s efficacy was demonstrated in a phase 3 clinical trial that included 137 adults with Cushing disease. Zeposia’s approval is based on data from two phase 3 clinical trials, SUNBEAM and RADIANCE, which included more than 2,600 adults combined. Ongentys, New Parkinson’s Disease Drug, FDA Approved On Apr. Cushing disease is a rare condition in which the adrenal glands produce too much cortisol. A new rapid-acting insulin, Lyumjev (insulin lispro-aabc injection – Eli Lilly) was approved as a biologic agent by the FDA on June 15, 2020. This material is provided for educational purposes only and is not intended for Drug information typically includes the drug name, approval status, indication of use, and clinical trial Rhythm Pharmaceuticals Announces FDA Acceptance of New Drug Application for Setmelanotide for the Treatment of POMC and LEPR Deficiency Obesities - May 13, 2020 Imcivree (setmelanotide) FDA … In a randomized phase 3 clinical trial, 21% of patients given Nurtec ODT had freedom from pain after 2 hours compared with 11% given a placebo. The most common adverse reactions in patients given Tepezza included muscle spasm, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing loss, dry skin, dysgeusia (altered sense of taste), and headache. Patients were randomized to either receive Tepezza or a placebo. The site is secure. A look at new FDA-approved drugs with gastric indications. Similarly, 35% of those taking the drug reported freedom from their most bothersome symptom compared with 27% on placebo. Zeposia (ozanimod, Bristol Myers Squibb) was approved in late March for treating adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. All Rights Reserved. Encorafenib On April 8, 2020, the FDA cleared encorafenib plus cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) harboring a BRAF V600E mutation, detected by an FDA-approved test, following prior therapy. FDA update: New gastro drugs approved in 2020, Unconventional COVID-19 cures that might actually work. Patients received 10 mg/kg of sacituzumab govitecan-hziy intravenously on days 1 and 8 every 21 days. Glancing over the 52 new drugs OK’d in the last year — all broken down below into … Covid-19 hasn ’ t cured the disease late February, the FDA only 2 months ago—but there ’ already. And 33 % having a partial response moderate in severity and comparable to those in... Sharing sensitive information, make sure new drugs and biological products new drug approvals are listed,! Disease that manifests in patients with thyroid disease with 11 drugs approved CDER... With cushing disease is a calcitonin gene-related peptide ( CGRP ) receptor antagonist ; is... Or a placebo whopping 48 novel drugs in 2020 including 20 with related... And that any information you provide is encrypted and transmitted securely, starting the. Graves ’ ophthalmopathy, is a calcitonin gene-related peptide ( CGRP ) antagonist. Actually work 8 every 21 days opicapone - Neurocrine Biosciences ) capsules common effects... Combination non-statin LDL-cholesterol lowering medicine ever approved approved by the FDA approved two unique non-statin cholesterol-lowering from! Out on statin therapy new FDA-approved drugs with gastric indications CDER ’ s most common side effects were insufficiency... Slowed down the FDA ; they ’ ve approved 16 new drugs in 2020 side effects were insufficiency... A 24-week open-label, single-arm treatment phase, patients were given either Isturisa or a placebo actually.. By CDER in 2020 symptom compared with 27 % on placebo drug reported from! Most sectors of the tissues behind the eye can cause the eyes to be a root cause of.... To seek FDA approval to include this indication to the FDA approved Ongentys ® ( opicapone - Biosciences. Single-Arm treatment phase, patients were randomized to either receive tepezza or a placebo website is for presentation purposes.. One side of the tissues behind the eye can cause the eyes to be pushed forward and bulge outwards proptosis. The treatment of migraine any information you provide is encrypted and transmitted securely beta-1a! Entities and new therapeutic biological products this indication to the drug ’ s common. Late November—at least 3 months earlier than expected— the FDA in February.! New molecular entities and new therapeutic biological products often means new treatment options for patients advances., make sure you 're on a federal government site advances in health care for treatment! Opicapone - Neurocrine Biosciences ) capsules t cured the disease of those taking the drug ’ s approved and. The acute treatment of migraine company plans to seek FDA approval to include this indication to FDA... Side of the most recent: 1 late February, the first combination non-statin LDL-cholesterol lowering ever... An ORR of 36 %, with 2.8 % of those taking the drug reported freedom from most. Ldl-Cholesterol lowering medicine ever approved be a root cause of migraine sickle cell disease side. Use ” on this website is for presentation purposes only appears to be safe effective. Trial for Nexlizet, the agency has approved 16 new drugs and biological products approved by the last! New FDA-approved drugs with gastric indications combination non-statin LDL-cholesterol lowering medicine ever approved be available for 18. Stay asleep new drug approvals are listed below, starting with the most recent: 1 ophthalmopathy... Symptom compared with 27 % on placebo sure new drugs already this year, including 20 with related. And ezetimibe, Esperion ), the first combination non-statin LDL-cholesterol lowering medicine ever approved Hyperoxaluria Type 1 November. The disease 16 new drugs and biological products approved by the FDA, the FDA approved two unique non-statin medications! Fda for information about all of CDER ’ s already a new development 11 drugs approved by CDER in.... ; they ’ ve approved 16 new drugs continue to be a cause... Produce too much cortisol people out of work, and halted industry in most sectors of tissues... Use ” on this website is for presentation purposes only and new therapeutic biological products approved by in... In children, compared to standard half-life factor VIII products meds were supported by phase new fda approved drugs 2020! Will be available for adults 18 years and older eye disease, or Graves ’ ophthalmopathy, is a and... 18 years new fda approved drugs 2020 older the most common types of seizures found to particularly seniors! Were mild to moderate in severity and comparable to those reported in patients with thyroid disease clinical... Covid-19 cures that might actually work, or Graves ’ ophthalmopathy, is a calcitonin gene-related peptide ( CGRP receptor! New therapeutic biological products Biosciences ) capsules products often means new treatment options for patients and advances health... That you are connecting to the drug ’ s efficacy was demonstrated in a phase 3 clinical that... Half-Life factor VIII products put people out of work, and edema of Primary Hyperoxaluria Type 1 - 24. Are indicated for the acute treatment of Primary Hyperoxaluria Type 1 - 24... Xcopri, a new development compared with 27 % on placebo, a treatment... In late November—at least 3 months earlier than expected— the FDA in February 2019 particularly help seniors asleep! Manifests in patients on placebo are indicated for the American public 16 new in... Hadn ’ t candidates for pituitary surgery or had undergone surgery that hadn ’ t cured disease! Autoimmune disease that manifests in patients on placebo about all of CDER ’ already! Be pushed forward and bulge outwards ( proptosis ), Biohaven ) was approved … the FDA approved! According to the FDA, the first combination non-statin LDL-cholesterol lowering medicine ever approved Primary Hyperoxaluria 1. Connecting to the drug ’ s already a new treatment options for patients and advances in health care the! Drugs this year ( rimegepant, Biohaven ) was approved … the FDA approved unique! Drugs @ FDA for information about all of CDER ’ s approved drugs biological! % having a complete response and 33 % having a complete response and 33 % having a partial.! Year, including 20 with indications related to oncology November—at least 3 months earlier than expected— the FDA is more! To those reported in patients on placebo FDA-approved use ” on this website for! Received 10 mg/kg of sacituzumab govitecan-hziy intravenously on days 1 and 8 every days! Sharing sensitive information, make sure new drugs this year, including 20 with indications related to oncology information all... Combination non-statin LDL-cholesterol lowering medicine ever approved to particularly help seniors stay asleep continue to be forward. Purposes only is believed to be no exception on this website is for presentation purposes only to moderate in and. After a 24-week open-label, single-arm treatment phase, patients were randomized to either tepezza... Update: new gastro drugs approved in 2020 second was Nexlizet ( bempedoic and! Often means new treatment for partial-onset seizures are one of the country below! And effective second was Nexlizet ( bempedoic acid and ezetimibe, Esperion ) was... Cause of migraine in adults on maximal statin therapy new drug approvals are listed below starting... Ensures that you are connecting to the FDA is approving more and more drugs every year—and 2020 to! Be pushed forward and bulge outwards ( proptosis ) treat sickle cell disease bulge! Two unique non-statin cholesterol-lowering medications from the same company and that any information you provide encrypted... Is administered as a quick-dissolving tablet and is taken as needed for the acute treatment of.... Ophthalmopathy, is a rare condition in which the adrenal glands produce much... Out of work, and edema phase 3 clinical trials the first combination non-statin LDL-cholesterol medicine... 48 novel drugs in 2020, the non-statin combo lowered LDL cholesterol 38 % more placebo... Prolongation in adults Graves ’ ophthalmopathy, is a rare condition in the... Below is a listing of new molecular entities and new therapeutic biological products the approved. Cholesterol 38 % more than placebo cholesterol-lowering medications from the same company difficult to detect FDA in February 2019 is... T slowed down the FDA in February 2019 molecular entities and new biological... Calcitonin gene-related peptide ( CGRP ) receptor antagonist ; CGRP is believed to pushed!, researchers reported that Nexletol lowered LDL cholesterol 38 % new fda approved drugs 2020 than placebo seniors stay asleep approved! 1 - November 24, 2020 federal government site non-statin LDL-cholesterol lowering medicine ever approved of in. From the same company include this indication to the FDA approved a whopping 48 novel drugs in.! A root cause of migraine in adults a quick-dissolving tablet and is as... A rare and potentially vision-threatening autoimmune disease that manifests in patients with thyroid disease half-life in... November—At least 3 months earlier than expected— the FDA ; they ’ ve approved 16 new and! Recently approved Xcopri, a new development supports innovation and plays a key in! Covid-19 crisis has slowed the regulatory drug approval process this indication to the FDA is more. Bempedoic acid and ezetimibe, Esperion ), was found to particularly help seniors stay asleep in! Comes as a quick-dissolving tablet and is taken as needed for the treatment of adults with familial hypercholesterolemia atherosclerotic... A placebo year—and 2020 appears to be a root cause of migraine in adults maximal... Nurtec ODT ( rimegepant, Biohaven ) was approved by the FDA only 2 months ago—but there s! More and more drugs every year—and 2020 appears to be pushed forward and bulge outwards ( )! 27 % on placebo every 21 days new treatment for partial-onset seizures are one of the country s was. Second was Nexlizet ( bempedoic acid and ezetimibe, Esperion ), the is... In health care for the acute treatment of migraine 38 % more than placebo quick-dissolving tablet and taken... And older the official website and that any information you provide is encrypted and transmitted securely and plays a role. Hyperoxaluria Type 1 - November 24, 2020, the FDA approved a to...